Sex and gender influence symptom manifestation and survival in multiple system atrophy.
Ataxia
Autonomic
Gender
Multiple system atrophy
Parkinsonism
Sex
Journal
Autonomic neuroscience : basic & clinical
ISSN: 1872-7484
Titre abrégé: Auton Neurosci
Pays: Netherlands
ID NLM: 100909359
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
13
12
2018
revised:
13
02
2019
accepted:
20
04
2019
entrez:
25
5
2019
pubmed:
28
5
2019
medline:
2
4
2020
Statut:
ppublish
Résumé
To evaluate the influence of sex and gender on clinical characteristics and survival in multiple system atrophy (MSA), we reviewed MSA patients with autonomic testing 1998-2012. Of 685 patients, 52% were male. Median survival overall was 7.3 years for males, 7.6 years for females. Survival from diagnosis was 2.9 years in males, 3.8 years in females. Females were more likely to initially manifest motor symptoms. Males were more likely to have orthostatic intolerance and early catheterization. In conclusion, our data show longer survival from diagnosis in females and slight overall survival benefit which may be related to initial motor manifestations.
Identifiants
pubmed: 31122601
pii: S1566-0702(18)30316-3
doi: 10.1016/j.autneu.2019.04.002
pmc: PMC6684211
mid: NIHMS1528180
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
49-52Subventions
Organisme : FDA HHS
ID : R01 FD004789
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS092625
Pays : United States
Organisme : NINDS NIH HHS
ID : U54 NS065736
Pays : United States
Organisme : NINDS NIH HHS
ID : K23 NS075141
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000135
Pays : United States
Organisme : NINDS NIH HHS
ID : P01 NS044233
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.
Références
Neurosci J. 2016;2016:2827090
pubmed: 27314003
Exp Physiol. 2016 Mar;101(3):349-55
pubmed: 26152788
Curr Urol. 2013 Feb;6(4):179-88
pubmed: 24917740
Neurourol Urodyn. 2014 Jun;33(5):516-23
pubmed: 23754466
Mov Disord. 2008 Jan 30;23(2):294-6
pubmed: 18044727
Mov Disord. 2014 Aug;29(9):1151-7
pubmed: 24909319
Auton Neurosci. 2016 Apr;196:75-80
pubmed: 26674572
Brain. 1994 Aug;117 ( Pt 4):835-45
pubmed: 7922469
J Clin Epidemiol. 2014 Aug;67(8):850-7
pubmed: 24831050
Neurology. 2008 Aug 26;71(9):670-6
pubmed: 18725592
Brain. 2002 May;125(Pt 5):1070-83
pubmed: 11960896
Brain. 2008 May;131(Pt 5):1362-72
pubmed: 18385183
Soc Sci Med. 1998 Apr;46(7):901-6
pubmed: 9541075
Mayo Clin Proc. 1993 Aug;68(8):748-52
pubmed: 8392653
Lancet Neurol. 2013 Mar;12(3):264-74
pubmed: 23391524
J Adv Nurs. 2005 Mar;49(6):616-23
pubmed: 15737222
Brain. 2015 Dec;138(Pt 12):3623-31
pubmed: 26369944
Lancet Neurol. 2015 Jul;14(7):710-9
pubmed: 26025783
J Neural Transm (Vienna). 2014 May;121(5):507-12
pubmed: 24337696
N Engl J Med. 2015 Jan 15;372(3):249-63
pubmed: 25587949
Mov Disord. 2011 Apr;26(5):909-12
pubmed: 21287601
Arch Neurol. 2007 Feb;64(2):256-60
pubmed: 17296842
Neurology. 1997 Feb;48(2):384-93
pubmed: 9040727